AU2007267561B2 - Low molecular weight heparin composition and uses thereof - Google Patents

Low molecular weight heparin composition and uses thereof Download PDF

Info

Publication number
AU2007267561B2
AU2007267561B2 AU2007267561A AU2007267561A AU2007267561B2 AU 2007267561 B2 AU2007267561 B2 AU 2007267561B2 AU 2007267561 A AU2007267561 A AU 2007267561A AU 2007267561 A AU2007267561 A AU 2007267561A AU 2007267561 B2 AU2007267561 B2 AU 2007267561B2
Authority
AU
Australia
Prior art keywords
lmwh
activity
reh
composition
ufh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007267561A
Other languages
English (en)
Other versions
AU2007267561A1 (en
Inventor
Corinne Bauer
Daniela Beccati
Ishan Capila
Ian Fier
Nur Sibel Gunay
Ying Li
Cuihua Liu
Zainab Sirajbhai Mamuwala
Patricia Oliver
Yi Wei Qi
Zachary Shriver
Mallik Sundaram
Ganesh Venkataraman
Yiming Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of AU2007267561A1 publication Critical patent/AU2007267561A1/en
Application granted granted Critical
Publication of AU2007267561B2 publication Critical patent/AU2007267561B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Polymers & Plastics (AREA)
  • Hospice & Palliative Care (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007267561A 2006-05-25 2007-05-24 Low molecular weight heparin composition and uses thereof Ceased AU2007267561B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US80913606P 2006-05-25 2006-05-25
US60/809,136 2006-05-25
US84957806P 2006-10-04 2006-10-04
US60/849,578 2006-10-04
US84962806P 2006-10-05 2006-10-05
US60/849,628 2006-10-05
PCT/US2007/069626 WO2007140231A2 (en) 2006-05-25 2007-05-24 Low molecular weight heparin composition and uses thereof

Publications (2)

Publication Number Publication Date
AU2007267561A1 AU2007267561A1 (en) 2007-12-06
AU2007267561B2 true AU2007267561B2 (en) 2012-05-17

Family

ID=38722686

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007267561A Ceased AU2007267561B2 (en) 2006-05-25 2007-05-24 Low molecular weight heparin composition and uses thereof

Country Status (7)

Country Link
US (2) US8609632B2 (cg-RX-API-DMAC7.html)
EP (3) EP2447285A3 (cg-RX-API-DMAC7.html)
JP (1) JP2009538386A (cg-RX-API-DMAC7.html)
CN (1) CN101495517B (cg-RX-API-DMAC7.html)
AU (1) AU2007267561B2 (cg-RX-API-DMAC7.html)
CA (1) CA2652205A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007140231A2 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478700C (en) 2002-03-11 2012-10-16 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
EP2447285A3 (en) 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US7790466B1 (en) 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009059284A2 (en) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009105522A1 (en) * 2008-02-20 2009-08-27 Momenta Pharmaceuticals, Inc. Methods of making low molecular weight heparin compositions
US20100036310A1 (en) * 2008-08-05 2010-02-11 Hillman Robert S Integrated patient management and control system for medication delivery
CN101711771B (zh) * 2008-10-07 2015-12-09 上海喜恩医药科技发展有限公司 一种肝素衍生的多糖混合物及其制法和药物组合物
EP2256138A1 (en) * 2009-05-05 2010-12-01 Sanofi-Aventis Novel acylated 1,6-anhhydro decasaccharide and its use as antithrombotic agent
EP2256136A1 (en) * 2009-05-05 2010-12-01 Sanofi-Aventis Novel acylated decasaccharides and their use as antithrombotic agents
EP2256137A1 (en) * 2009-05-05 2010-12-01 Sanofi-Aventis Novel sulfated octasaccharide and its use as antithrombotic agent
EP2256139A1 (en) * 2009-05-05 2010-12-01 Sanofi-Aventis Novel sulfated heptasaccharide and its use as antithrombotic agent
US8834807B2 (en) * 2009-08-12 2014-09-16 Caliper Life Sciences, Inc. Device and method for improving sample injection and stacking
FR2949114B1 (fr) * 2009-08-14 2011-08-26 Sanofi Aventis OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2011031301A2 (en) * 2009-08-28 2011-03-17 Mount Sinai School Of Medicine Of New York University Intrapericardial delivery of periostin
WO2011038047A1 (en) * 2009-09-23 2011-03-31 Momenta Pharmaceuticals, Inc. Methods of treatment with a low molecular weight heparin composition
RU2576033C2 (ru) 2009-12-03 2016-02-27 Опко Хелс, Инк. Составы на основе гиперсулфатированных дисахаридов
ES2817779T3 (es) * 2010-01-19 2021-04-08 Momenta Pharmaceuticals Inc Evaluación de preparaciones de heparina
US9387256B2 (en) 2010-04-16 2016-07-12 Momenta Pharmaceuticals, Inc. Tissue targeting
JP5905455B2 (ja) 2010-06-17 2016-04-20 モメンタ ファーマシューティカルズ インコーポレイテッド 発毛を促進する方法および組成物
ES2910476T3 (es) 2010-12-23 2022-05-12 Univ North Carolina Chapel Hill Síntesis quimioenzimática de heparinas de peso molecular ultra bajo estructuralmente homogéneas
UA112070C2 (uk) * 2011-01-28 2016-07-25 Хангжоу Джіуюан Джін Енджініерінг Ко., Лтд Спосіб капілярного електрофорезу для аналізу тонкої структури еноксапарину натрію
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
WO2013095279A1 (en) * 2011-12-19 2013-06-27 Dilafor Ab Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
CN103059165B (zh) * 2012-12-26 2015-04-29 安徽丰原药业股份有限公司 一种多糖酰化物及其制备方法
CN103204958B (zh) * 2013-04-24 2015-04-01 深圳赛保尔生物药业有限公司 一种低乙醇残留的那曲肝素钙生产工艺
CA2910837A1 (en) 2013-05-28 2014-12-04 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
CN105452479B (zh) 2013-06-17 2021-05-18 北卡罗来纳大学查珀尔希尔分校 可逆肝素分子
CN103788232A (zh) * 2013-12-23 2014-05-14 深圳市海普瑞药业股份有限公司 一种硫酸乙酰肝素十糖及其制备方法和应用
CN104193849B (zh) * 2014-08-13 2016-08-17 南京健友生化制药股份有限公司 一种依诺肝素钠的生产方法
US10688249B2 (en) * 2015-06-11 2020-06-23 Virchow Biotech Pvt. Ltd. Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same
US20190002596A1 (en) * 2015-12-30 2019-01-03 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Sulfated heparin oligosaccharide and preparation method and application thereof
CN105504097B (zh) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 一种硫酸化肝素寡糖及其制备方法和应用
EP3401686B1 (en) * 2016-01-07 2022-10-05 Fujimori Kogyo Co., Ltd. Method for analyzing blood characteristics
CN105461831A (zh) * 2016-01-08 2016-04-06 东营天东制药有限公司 一种快速分离快速移动肝素与硫酸皮肤素的方法
RU2641058C1 (ru) * 2016-11-17 2018-01-15 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ профилактики венозной тромбоэмболии у больных раком шейки матки
CN108117614B (zh) * 2016-11-29 2020-09-04 北京碧澄生物科技有限公司 低分子量肝素
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
JP7330893B2 (ja) 2017-03-10 2023-08-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 短時間作用型ヘパリンベースの抗凝集剤化合物及び方法
WO2019010216A1 (en) 2017-07-03 2019-01-10 The University Of North Carolina At Chapel Hill ENZYMATIC SYNTHESIS OF HOMOGENEOUS CHONDROITIN SULFATE OLIGOSACCHARIDES
JP7495061B2 (ja) 2017-11-03 2024-06-04 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 抗炎症作用を有する硫酸化オリゴ糖
EP3810152A4 (en) 2018-06-20 2022-04-27 The University of North Carolina at Chapel Hill CELL PROTECTION METHODS AND COMPOSITIONS
CN114616340A (zh) 2019-07-09 2022-06-10 奥普蒂姆维亚有限公司 合成抗凝血多糖的方法
US20230241095A1 (en) * 2020-06-12 2023-08-03 Ihp Therapeutics Inc. Partially desulfated heparin for treating coronaviral infections
EP4182452A4 (en) 2020-07-14 2024-07-31 Optimvia, LLC METHOD FOR THE SYNTHESIS OF NON-ANTICOAGULATING HEPARAN SULFATE
CA3217273A1 (en) * 2021-05-12 2022-11-17 Li Fu Methods of manufacturing a high molecular weight heparin compound
KR20250063537A (ko) * 2023-11-01 2025-05-08 건국대학교 글로컬산학협력단 저분자량 헤파린 및 지질이 결합되어 자가 조립된 나노 입자, 이의 제조방법 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055515A1 (en) * 1997-06-06 1998-12-10 Hamilton Civic Hospitals Research Development, Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
US5849721A (en) * 1992-02-07 1998-12-15 Rhone-Poulenc Rorer S.A. Sulfated polysaccharides obtained from heparin, preparation process, pharmaceutical composition and use thereof
WO2001002443A1 (en) * 1999-06-30 2001-01-11 Hamilton Civic Hospitals Research Development, Inc Heparin compositions that inhibit clot associated coagulation factors
US6608042B2 (en) * 2000-03-28 2003-08-19 Aventis Pharma, S.A. Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof
US20030203385A1 (en) * 2002-03-11 2003-10-30 Ganesh Venkataraman Analysis of sulfated polysaccharides

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK196986D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
FR2663639B1 (fr) 1990-06-26 1994-03-18 Rhone Poulenc Sante Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation.
US5707973A (en) * 1991-04-23 1998-01-13 Rhone-Poulenc Rorer S.A. Sulfated polysaccharids for treatment or prevention of thromboses
FR2687158B1 (fr) 1992-02-07 1995-06-30 Rhone Poulenc Rorer Sa Polysaccharides sulfates, procede de preparation, composition pharmaceutique et utilisation.
US5681733A (en) 1994-06-10 1997-10-28 Ibex Technologies Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum
FR2723847A1 (fr) * 1994-08-29 1996-03-01 Debiopharm Sa Compositions antithrombotiques et non hemorragiques a base d'heparine, procede pour leur preparation et applications therapeutiques.
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US20010046974A1 (en) * 1997-06-06 2001-11-29 Hamilton Civic Hospitals Res Dev., Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
US5896789A (en) 1997-10-09 1999-04-27 Chicago Pneumatic Tool Company Ratchet wrench head
JP4226101B2 (ja) 1998-05-12 2009-02-18 株式会社アルバック 静電チャックプレート表面からの基板離脱方法
US20020009782A1 (en) * 1999-06-03 2002-01-24 Daphna Miron Heparin and heparan sulfate derived oligosaccharides and a method for their manufacture
WO2001051525A1 (de) 2000-01-10 2001-07-19 Dieter Welzel Heparin mit mittlerer molmasse
WO2001066772A2 (en) * 2000-03-08 2001-09-13 Massachusetts Institute Of Technology Heparinase iii and uses thereof
FR2811992B1 (fr) * 2000-07-21 2003-07-04 Aventis Pharma Sa Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
US6969705B2 (en) * 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
DK1319183T3 (da) 2000-09-12 2009-05-18 Massachusetts Inst Technology Fremgangsmåder og produkter relateret til heparin med lav molekylvægt
EP1328260A2 (en) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
AU2002338454A1 (en) * 2001-04-03 2002-11-05 Rx-Connect, Inc. Permission based marketing for use with medical prescriptions
JP2005505537A (ja) * 2001-08-28 2005-02-24 レオ・ファーマ・アクティーゼルスカブ 低分子量ヘパリンと低分子量デルマタン硫酸とを含む抗血栓組成物
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
FR2845686B1 (fr) * 2002-10-10 2013-08-30 Aventis Pharma Sa Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
FR2857971B1 (fr) * 2003-07-24 2005-08-26 Aventis Pharma Sa Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
CN1268650C (zh) * 2003-12-24 2006-08-09 兆科药业（合肥）有限公司 一种低亚硝酸盐含量的低分子肝素钙的制备方法
RU2295538C2 (ru) 2005-03-01 2007-03-20 Гематологический научный центр РАМН Способ получения гепаринов с низкой молекулярной массой
DK2848938T3 (da) * 2006-04-24 2017-11-13 Critical Care Diagnostics Inc Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
EP2447285A3 (en) 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849721A (en) * 1992-02-07 1998-12-15 Rhone-Poulenc Rorer S.A. Sulfated polysaccharides obtained from heparin, preparation process, pharmaceutical composition and use thereof
WO1998055515A1 (en) * 1997-06-06 1998-12-10 Hamilton Civic Hospitals Research Development, Inc. Modified low molecular weight heparin that inhibits clot associated coagulation factors
WO2001002443A1 (en) * 1999-06-30 2001-01-11 Hamilton Civic Hospitals Research Development, Inc Heparin compositions that inhibit clot associated coagulation factors
US6608042B2 (en) * 2000-03-28 2003-08-19 Aventis Pharma, S.A. Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof
US20030203385A1 (en) * 2002-03-11 2003-10-30 Ganesh Venkataraman Analysis of sulfated polysaccharides

Also Published As

Publication number Publication date
CA2652205A1 (en) 2007-12-06
JP2009538386A (ja) 2009-11-05
EP2019843A2 (en) 2009-02-04
AU2007267561A1 (en) 2007-12-06
WO2007140231A2 (en) 2007-12-06
WO2007140231A3 (en) 2008-12-04
US8609632B2 (en) 2013-12-17
EP2447285A3 (en) 2013-01-16
EP2447285A2 (en) 2012-05-02
CN101495517B (zh) 2012-10-10
US20070287683A1 (en) 2007-12-13
CN101495517A (zh) 2009-07-29
EP2404939A2 (en) 2012-01-11
US20100305022A1 (en) 2010-12-02
EP2404939A3 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
AU2007267561B2 (en) Low molecular weight heparin composition and uses thereof
US9351992B2 (en) Non-anticoagulant polysaccharide compositions
JP4828795B2 (ja) 硫酸化多糖類の分析
JP5351770B2 (ja) ビオチンまたはビオチン誘導体との少なくとも１つの共有結合を含む低分子量ヘパリン、これらの作製方法およびそれらの使用。
IE66341B1 (en) Mixtures of low molecular weight polysaccharides and their preparation and use
US20110076729A1 (en) Methods of making low molecular weight heparin compositions
Fareed et al. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile
US5721357A (en) Preparation of sulfated polysaccharides for treatment or prevention of thromboses
US20120322760A1 (en) Methods of treatment with a low molecular weight heparin composition
Mousa The low molecular weight heparin, tinzaparin, in thrombosis and beyond
AU671817B2 (en) Sulphated polysaccharides, preparation thereof, pharmaceutical composition and use thereof
US7008933B2 (en) Process for prophylaxis and therapy of thrombotic processes employing heparin having particular average molecular weights
RU2451515C2 (ru) Композиции гепарина низкой молекулярной массы и их применение
Fareed et al. Low molecular weight heparins: a developmental perspective
Green The heparins: Basic and clinical aspects
HK1134934A (en) Low molecular weight heparin composition and uses thereof
Jeske et al. Pharmacologic profile of a low-molecular-weight heparin depolymerized by γ-irradiation
Hernaningsih et al. Examination of Laboratory for Monitoring Heparin Anticoagulant
Lee Dalteparin sodium in the management of thromboembolic disorders
JP2002080371A (ja) プラスミノーゲンアクチベーター活性促進剤
Doutremepuich et al. Laboratory control of heparin and heparin fragment treatment: an experimental study
HK1140220A (en) Low molecular weight heparins including at least one covalent bond with biotin or a biotin derivative, method for making same and use thereof
HK1199893A1 (en) Use of chemically modified heparin derivates in sickle cell disease
HK1139587A (en) Heparins including at least one covalent bond with biotin or a biotin derivative, method for preparing same and use thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND APPLICANT NAME FROM: MOMENTA PHARMACEUTICAL, INC. TO MOMENTA PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired